PBYI Stock Summary and Trading Ideas (Puma Biotechnology | NASDAQ:PBYI)

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Puma Biotechnology trades on the NASDAQ stock market under the symbol PBYI.

As of March 26, 2026, PBYI stock price declined to $6.27 with 176,905 million shares trading.

PBYI has a beta of 1.21, meaning it tends to be more sensitive to market movements. PBYI has a correlation of 0.08 to the broad based SPY ETF.

PBYI has a market cap of $315.82 million. This is considered a Small Cap stock.

Last quarter Puma Biotechnology reported $76 million in Revenue and $.29 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.08.

In the last 3 years, PBYI traded as high as $7.73 and as low as $2.13.

The top ETF exchange traded funds that PBYI belongs to (by Net Assets): AVUV, VTI, IWM, VXF, IWN.

PBYI has outperformed the market in the last year with a price return of +92.9% while the SPY ETF gained +13.4%. PBYI has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +5.2% and +4.5%, respectively, while the SPY returned -6.3% and -4.4%, respectively.

PBYI support price is $6.10 and resistance is $6.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PBYI shares will trade within this expected range on the day.